title: Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
abstract: New Zealand White (NZW) rabbits were immunized with several different nontoxic botulinum neurotoxin serotype B (BoNT/B) preparations in an effort to optimize the production of a rapid and highly potent, effective neutralizing antibody response. The immunogens included a recombinant heavy chain (rHc) protein produced in Escherichia coli, a commercially available formaldehyde-inactivated toxoid, and an alkylated toxoid produced by urea-iodoacetamide inactivation of the purified active toxin. All three immunogens elicited an antibody response to BoNT/B, detected by enzyme-linked immunosorbent assay (ELISA) and by toxin neutralization assay, by the use of two distinct mouse toxin challenge models. The induction period and the ultimate potency of the observed immune response varied for each immunogen, and the ELISA titer was not reliably predictive of the potency of toxin neutralization. The kinetics of the BoNT/B-specific binding immune response were nearly identical for the formaldehyde toxoid and alkylated toxoid immunogens, but immunization with the alkylated toxoid generated an approximately 10-fold higher neutralization potency that endured throughout the study, and after just 49 days, each milliliter of serum was capable of neutralizing 10(7) 50% lethal doses of the toxin. Overall, the immunization of rabbits with alkylated BoNT/B toxoid appears to have induced a neutralizing immune response more rapid and more potent than the responses generated by vaccination with formaldehyde toxoid or rHc preparations.
authors.affiliation: Biosciences Division, SRI International, 333 Ravenswood Ave., Menlo Park, CA 94025, USA.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Held
authors.forename: Amy C
authors.initials: AC
authors.lastname: Shurtleff
authors.forename: Scott
authors.initials: S
authors.lastname: Fields
authors.forename: Christopher
authors.initials: C
authors.lastname: Green
authors.forename: Julie
authors.initials: J
authors.lastname: Fong
authors.forename: Russell G A
authors.initials: RG
authors.lastname: Jones
authors.forename: Dorothea
authors.initials: D
authors.lastname: Sesardic
authors.forename: Roland
authors.initials: R
authors.lastname: Buelow
authors.forename: Rae Lyn
authors.initials: RL
authors.lastname: Burke
mesh_terms: D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D001905:Botulinum Toxins / Q000276:immunology* / Q000633:toxicity; D019274:Botulinum Toxins, Type A; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007460:Iodoacetamide / Q000494:pharmacology*; D051379:Mice; D009500:Neutralization Tests; D011817:Rabbits; D013997:Time Factors; D014121:Toxoids / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology
chemical_list: D000477:Alkylating Agents; D000907:Antibodies, Bacterial; D057134:Antibodies, Neutralizing; D014121:Toxoids; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; D007460:Iodoacetamide
references.citation: Infect Immun. 1991 Feb;59(2):625-30
references.pmid: 1702767
references.citation: Protein Expr Purif. 2004 Mar;34(1):8-16
references.pmid: 14766296
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50
references.pmid: 12177434
references.citation: Vaccine. 2007 May 22;25(21):4273-82
references.pmid: 17395341
references.citation: Protein Expr Purif. 2004 Mar;34(1):95-102
references.pmid: 14766304
references.citation: Infect Immun. 2003 May;71(5):2941-4
references.pmid: 12704175
references.citation: Comp Immunol Microbiol Infect Dis. 2009 Mar;32(2):107-21
references.pmid: 18243312
references.citation: Nat Biotechnol. 2007 Jan;25(1):107-16
references.pmid: 17173035
references.citation: Infect Immun. 2008 Jan;76(1):437-42
references.pmid: 17967862
references.citation: Protein Expr Purif. 2006 Apr;46(2):256-67
references.pmid: 16297638
references.citation: Crit Rev Immunol. 2007;27(4):303-18
references.pmid: 18197811
references.citation: Cell Res. 2002 Jun;12(2):157-60
references.pmid: 12118942
references.citation: J Pharm Technol. 1989 Jul-Aug;5(4):181-6
references.pmid: 10314382
references.citation: Clin Infect Dis. 1996 Aug;23(2):337-40
references.pmid: 8842274
references.citation: Protein Expr Purif. 2006 Feb;45(2):288-95
references.pmid: 16143544
references.citation: Microbiol Rev. 1982 Mar;46(1):86-94
references.pmid: 6806598
references.citation: Curr Top Microbiol Immunol. 1995;195:55-75
references.pmid: 8542759
references.citation: Infect Immun. 2007 Jun;75(6):3043-54
references.pmid: 17371853
references.citation: J Clin Microbiol. 1988 Nov;26(11):2351-6
references.pmid: 3235662
references.citation: Cloning Stem Cells. 2007 Spring;9(1):12-6
references.pmid: 17386007
references.citation: J Cell Sci. 1999 Aug;112 ( Pt 16):2715-24
references.pmid: 10413679
references.citation: Crit Rev Microbiol. 2005;31(1):11-8
references.pmid: 15839401
references.citation: Infect Immun. 1995 Jul;63(7):2738-42
references.pmid: 7790092
references.citation: J Protein Chem. 2000 Aug;19(6):475-87
references.pmid: 11195972
references.citation: J Protein Chem. 2000 Nov;19(8):699-707
references.pmid: 11307955
references.citation: Biologicals. 2006 Sep;34(3):223-6
references.pmid: 16490362
references.citation: Vaccine. 2002 Jun 7;20(19-20):2556-61
references.pmid: 12057613
references.citation: J Clin Microbiol. 1989 Aug;27(8):1906-8
references.pmid: 2768475
references.citation: Toxicon. 2006 Sep 1;48(3):246-54
references.pmid: 16870221
references.citation: Infect Immun. 2008 Mar;76(3):1314-8
references.pmid: 18070903
references.citation: J Immunol Methods. 2008 Aug 20;337(1):42-8
references.pmid: 18571196
references.citation: Vaccine. 2007 Oct 23;25(43):7540-8
references.pmid: 17897756
references.citation: Trends Biochem Sci. 2002 Nov;27(11):552-8
references.pmid: 12417130